Progressive thoughts about progressive disease. Read more about Progressive thoughts about progressive disease.
CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Read more about CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility.
Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Read more about Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Read more about MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Read more about Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
Multiple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients. Read more about Multiple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients.
Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Read more about Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Read more about Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Read more about Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Read more about The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
